Skip to main content
NCBI home page
Journal of Epidemiology and Community Health logoLink to Journal of Epidemiology and Community Health
. 1990 Dec;44(4):274–280. doi: 10.1136/jech.44.4.274

Costs and benefits of a second measles inoculation of children in Israel, the West Bank, and Gaza.

G M Ginsberg 1, T H Tulchinsky 1
PMCID: PMC1060669  PMID: 2126028

Abstract

STUDY OBJECTIVE--Measles has been targeted by the WHO as a disease which should be eradicated. Use of existing vaccines during infancy has resulted in a substantial decline in cases in Israel, the West Bank, and Gaza. However the disease continues to occur in epidemic waves with large scale morbidity and mortality in all of these populations. This paper estimates the costs and benefits of three alternative strategies of adding immunisation at school age, and during young adult life to the present vaccination at 15 months. MEASUREMENTS AND MAIN RESULTS--A policy of immunising all Israeli children aged 6 (option A) would cost around $1 million and have estimated benefits of $4.5 million, yielding a benefit cost ratio of 4.53/1. Despite relatively lower medical care costs and work absence costs (as a result of the lower per capita GNP and lower female participation rate in the workforce), the West Bank and Gaza situations yield benefit to cost ratios of 5.74/1 and 9.59/1 respectively because of their relatively higher incidence rates. If implemented in Israel, a vaccination programme (such as option A) would prevent, over the next 10 years, approximately 28,700 simple cases, 3400 hospital admissions, eight non-fatal cases of encephalitis, and 2.2 cases of SSPE. It would save 28 lives. The adoption of option A, is expected to reduce incidence and mortality by around 13,600 and 32 cases in the West Bank, and by 18,000 and 64 cases in Gaza. CONCLUSION--The adoption of a two dose policy appears to be economically justifiable.

Full text

PDF
274

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albritton R. B. Cost-benefits of measles eradication: effects of a federal intervention. Policy Anal. 1978 Winter;4(1):1–21. [PubMed] [Google Scholar]
  2. Assaad F. Measles: summary of worldwide impact. Rev Infect Dis. 1983 May-Jun;5(3):452–459. doi: 10.1093/clinids/5.3.452. [DOI] [PubMed] [Google Scholar]
  3. Axnick N. W., Shavell S. M., Witte J. J. Benefits due to immunization against measles. Public Health Rep. 1969 Aug;84(8):673–680. [PMC free article] [PubMed] [Google Scholar]
  4. Frank J. A., Jr, Orenstein W. A., Bart K. J., Bart S. W., el-Tantawy N., Davis R. M., Hinman A. R. Major impediments to measles elimination. The modern epidemiology of an ancient disease. Am J Dis Child. 1985 Sep;139(9):881–888. doi: 10.1001/archpedi.1985.02140110035024. [DOI] [PubMed] [Google Scholar]
  5. Hopkins D. R., Hinman A. R., Koplan J. P., Lane J. M. The case for global measles eradication. Lancet. 1982 Jun 19;1(8286):1396–1398. doi: 10.1016/s0140-6736(82)92510-7. [DOI] [PubMed] [Google Scholar]
  6. Mathias R. G., Meekison W. G., Arcand T. A., Schechter M. T. The role of secondary vaccine failures in measles outbreaks. Am J Public Health. 1989 Apr;79(4):475–478. doi: 10.2105/ajph.79.4.475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Rabo E., Taranger J. Scandinavian model for eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 1984 Nov 24;289(6456):1402–1404. doi: 10.1136/bmj.289.6456.1402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Swartz T. A. Prevention of measles in Israel: implications of a long-term partial immunization program. Public Health Rep. 1984 May-Jun;99(3):272–277. [PMC free article] [PubMed] [Google Scholar]
  9. White C. C., Koplan J. P., Orenstein W. A. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health. 1985 Jul;75(7):739–744. doi: 10.2105/ajph.75.7.739. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Willems J. S., Sanders C. R. Cost-effectiveness and cost-benefit analyses of vaccines. J Infect Dis. 1981 Nov;144(5):486–493. doi: 10.1093/infdis/144.5.486. [DOI] [PubMed] [Google Scholar]
  11. Witte J. J., Axnick N. W. The benefits from 10 years of measles immunization in the United States. Public Health Rep. 1975 May-Jun;90(3):205–207. [PMC free article] [PubMed] [Google Scholar]
  12. Zilber N., Rannon L., Alter M., Kahana E. Measles, measles vaccination, and risk of subacute sclerosing panencephalitis (SSPE). Neurology. 1983 Dec;33(12):1558–1564. [PubMed] [Google Scholar]

Articles from Journal of Epidemiology and Community Health are provided here courtesy of BMJ Publishing Group

RESOURCES